NDAINJECTIONSOLUTIONPriority Review
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGGRASTAT (tirofiban) is a small-molecule glycoprotein IIb/IIIa inhibitor administered intravenously to prevent blood clots during percutaneous coronary intervention (PCI) in acute coronary syndrome patients. It works by blocking platelet aggregation, reducing the risk of thrombotic complications in high-risk interventional cardiology patients.
LOE Approaching
As a mature injectable product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams are likely in defensive positioning with streamlined staffing focused on clinical differentiation and outcomes data.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Tirofiban After Successful MT Recanalization in AIS
Started Apr 2024
1,380 enrolled
Acute Ischemic StrokeVessel Occlusion
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Started Nov 2023
516 enrolled
Branch Atheromatous Disease
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
Started Aug 2017
10 enrolled
Non-ST Elevation Myocardial Infarction (NSTEMI)
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Started Jan 2013
25 enrolled
Renal Insufficiency
Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
Started Aug 2012
100 enrolled
Non-ST Segment Elevation Acute Coronary Syndrome
Worked on AGGRASTAT at Medicure? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.